Project Grant R01CA308444
Award Date 4/1/26
Completion Date 3/31/31
Dollars Obligated $461K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Little Rock, AR 72205, USA
Similar Awards
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Arkansas for Medical Sciences $420,335 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on June 23, 2025, for a project period extending through May 31, 2027. The project investigates the role of lytic viral genes in the pathogenesis of oncogenic gammaherpesviruses, specifically examining whether lytic gene expression drives the development and...
- Federal Grant Award Summary Fred Hutchinson Cancer Center received a $432,098 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) on August 4, 2025, with an ultimate completion date of July 31, 2027. This award supports research investigating HIV persistence and treatment response in Kaposi Sarcoma (KS), a condition caused by Kaposi Sarcoma Herpesvirus (KSHV) that disproportionately affects people with HIV (PWH), particularly in sub-Saharan...
- Federal Grant Award Summary The National Cancer Institute (NCI), under its Cancer Biology Research program (CFDA 93.396), awarded a $661,721 Project Grant to the University of California, San Diego, with an award date of April 1, 2026, and a completion date of March 31, 2031. This five-year research initiative focuses on systematic functional mapping and interrogation of oncogenic intrinsically disordered regions (IDRs) in cancer driver proteins. The project will utilize novel high-throughput...
- Federal Grant Award Summary The National Cancer Institute awarded Tufts University School of Medicine a Project Grant totaling $415,994 under the Cancer Biology Research program (CFDA 93.396) for the period May 1, 2026 through April 30, 2031. This grant funds fundamental research investigating the role of ASAH1-driven ceramide metabolism in Epstein-Barr Virus (EBV) B-cell transformation within the germinal center microenvironment under physiologically relevant hypoxic conditions. The research...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Missouri System $486,426 under the Cancer Biology Research program (CFDA 93.396) for a five-year project grant (April 1, 2026 – March 31, 2031) investigating leukemic stem cell (LSC) interactions within the bone marrow microenvironment. The research focuses on elucidating molecular interactions between N-cadherin-expressing bone marrow mesenchymal stem cells (N-CAD+ MSCs) and LSCs, with particular...
- Federal Grant Award Summary The National Cancer Institute awarded a Project Grant of $420,505 to the University of California, San Diego, under the Cancer Treatment Research program (CFDA 93.395) for the period April 1, 2026 through March 31, 2028. The award supports research into plant virus-based adjuvants as therapeutic agents, with particular focus on understanding Cowpea Mosaic Virus (CPMV) as an immunomodulator for infectious disease and cancer vaccines. The research project will...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Pittsburgh a $151,920 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective September 1, 2025, through August 31, 2027. This award supports fundamental research to develop and validate Nuclear Magnetic Resonance (NMR) strategies for investigating allosteric inhibitor binding effects on Src-family kinases implicated in acute myeloid leukemia (AML). The research aims to characterize...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $495,715 to the Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) on August 5, 2025, with a completion date of July 31, 2030. This award funds fundamental research to decipher the pathogenesis and therapeutic vulnerabilities in germline RUNX1-mutated acute myeloid leukemia (AML). The research focuses on understanding how germline RUNX1 mutations...
- Federal Grant Award Summary The University of Arkansas for Medical Sciences (UAMS) received a $1.15M Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective August 1, 2025, through May 31, 2030. This Phase III COBRE (Centers of Biomedical Research Excellence) award funds the Center for Studies of Host Response to Cancer Therapy, which develops research infrastructure, support...
- Federal Grant Award Summary Baylor College of Medicine received a $160,500 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective July 10, 2025, with completion targeted for June 30, 2027. The award funds the development and investigation of in vivo murine models to examine the role of caspase-2 in nucleophosmin-mutated acute myeloid leukemia (NPM1C+ AML). The research deliverables include the establishment of transgenic mouse...